Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Northwest Biotherapeutics Scaled Net Operating Assets Related Terms
Northwest Biotherapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Northwest Biotherapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics Scaled Net Operating Assets Chart
NWBO vs LCTX, VRXA, ABEO: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Northwest Biotherapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.14 mean?
Northwest Biotherapeutics (NWBO) has a Scaled Net Operating Assets of 0.14 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Northwest Biotherapeutics and its competitors.
Is Northwest Biotherapeutics' Scaled Net Operating Assets too high?
Northwest Biotherapeutics' current Scaled Net Operating Assets is 0.14. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Scaled Net Operating Assets compare to LCTX and VRXA?
Northwest Biotherapeutics' Scaled Net Operating Assets of 0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Scaled Net Operating Assets is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current Scaled Net Operating Assets of 0.14. The current Scaled Net Operating Assets is 0.14. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current Scaled Net Operating Assets is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score
Get the complete analysis for NWBO
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NWBO has been successfully added to your 
